AKBA - CIK 0001517022
Akebia Therapeutics, Inc. trades as AKBA. In its fiscal 2025 annual report the company posted revenue of $236.20M, up 47.5% from the prior year and net income of -$5.30M. This page tracks Akebia Therapeutics, Inc. through 868 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Akebia Therapeutics, Inc.'s revenue grew from $1.53M to $236.20M, a compound annual growth rate of 75.0%. Net profit margin expanded from -8843.5% to -2.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| PRE 14A | - | 2026-04-15 |
| Insider trade | 4 | 2026-04-03 |
The largest companies sharing Akebia Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Akebia Therapeutics, Inc. reported revenue of $236.20M for fiscal year 2025, an increase of 47.5% year over year.
In its latest fiscal year Akebia Therapeutics, Inc. reported a net loss of $5.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.